Finchley Healthcare Ventures

Finchley Healthcare Ventures

Founded around the legacy of Pharmascience Inc., Finchley Healthcare Ventures sits at the intersection of a major Canadian pharmaceutical operating company and a disciplined life-science investment vehicle. The firm is anchored by Pharmascience's leadership; Dr. David Goodman, who led Pharmascience as CEO from 2006 to 2022, and his father Morris Goodman, who co-founded the parent company in 1983, provide the strategic continuity. The investment team is led by Pierre Beauparlant, Ph.D., a former venture partner at Sanderling Ventures, a San Francisco Bay area life-science fund. This structure places deep pharmaceutical operational knowledge directly on the investment committee. The firm deploys capital across two tracks: direct equity investments in emerging drug-development companies and commitments to external venture capital funds specializing in life sciences. Its direct investments target therapies with a novel mechanism that address significant unmet medical needs, spanning both established modalities like small molecules and antibodies, and frontier approaches including nanotechnologies. Finchley will invest at a company's first clinical trial or later stages, with the goal of demonstrating human proof of concept. While specific portfolio company names are not publicly disclosed on its website, the firm operates with no geographical restriction, sourcing opportunities from scientists and entrepreneurs in North America, Europe, and globally. The team's access to Pharmascience's internal network of pharmaceutical development, manufacturing, and regulatory experts provides a non-capital resource base that differentiates its value proposition to founders. Finchley's internal bench combines investment and scientific talent. The team includes a Senior Analyst with a Ph.D. in Human Genetics and policy experience at Imagia Canexia Health, and an Investment Analyst with a Ph.D. in Microbiology who served as Programming Chair for the Greater-Montreal Women in Bio chapter. Financial operations are managed by a CFA charterholder and a CPA auditor who joined in 2023 and 2025, respectively, both holding roles previously at Pharmascience. The firm does not publicly report its assets under management or total deployment. Its governance board includes a senior investment banker from Greenhill & Co. specializing in biotechnology and generics, and a former Teva Pharmaceuticals Senior Vice President, linking the firm to both Wall Street and global generic-drug markets. Philanthropic activities associated with the principals, such as the Rosalind and Morris Goodman Cancer Institute at McGill University, operate through a separate family foundation. Finchley's architecture is that of a venture platform embedded within an operational pharmaceutical group rather than a standalone fund manager. This hybrid model gives the firm a dual lens: an operator's view of clinical and regulatory risk and an investor's discipline on capital allocation. The presence of a managing partner with Bay-area venture experience and a board stacked with pharma transaction expertise creates a governance blend that is rare in Canadian healthcare investing — neither pure captive family office nor independent institutional fund.